on PinterestAddyi, sometimes referred to as “female Viagra,” is now approved for use to treat low sex drive in postmenopausal women.
on PinterestAddyi, sometimes referred to as “female Viagra,” is now approved for use to treat low sex drive in postmenopausal women. MoMo Productions/Getty Images
- The FDA expanded its approval of Addyi, a pill to treat low libido in women, to include postmenopausal women up to age 65.
- The approval will open up new treatment options for older women, but experts caution that treating low libido requires a “whole body approach.”
- It’s recommended to avoid taking Addyi within two hours of consuming alcohol to avoid potential interactions and dangerous side effects.
The Food and Drug Administration (FDA) expanded its approval of a daily pill to treat low libido in females to include postmenopausal women up to age 65.
Prior to the announcement this week, the pill, Addyi (flibanserin), was only approved to treat hypoactive sexual desire disorder (HSDD) in premenopausal females.
The drug was first approved by the FDA in 2015, following a lengthy and contentious review process.
The FDA previously rejected the drug on two separate occasions, in 2010 and 2013. In both cases, the agency raised concerns about safety, efficacy, and an unfavorable risk–benefit profile.
Today, Addyi is the only FDA-approved oral medication for HSDD, though the FDA approved Vyleesi (bremelanotide), an as-needed injectable treatment, in 2019.
Cindy Eckert, founder and CEO of Sprout Pharmaceuticals, the maker of Addyi, praised the FDA’s decision to expand the drug’s approval in a press release, calling it a “milestone” in understanding and prioritizing female sexual health.
Other women’s health experts expressed support for the decision.
“There was nothing really for me to prescribe because everything was for women who were menstrual and not menopausal,” said G. Thomas Ruiz, MD, an OB-GYN at MemorialCare Orange Coast Medical Center in Fountain Valley, CA. “Getting the FDA approval for this patient population could be very important to address postmenopausal women who want to have sexual activity and enjoy sex, but sometimes have issues with libido.”
Mary Jane Minkin, MD, a clinical professor in the department of obstetrics, gynecology, and reproductive sciences at Yale University, told Healthline that the approval was “quite reasonable” given the available data.
“The studies showed statistical significance of the drug over the placebo, but the magnitude of the improvement is not overwhelming,” Minkin said.
What is Addyi, the ‘female Viagra’?
Addyi, which is sometimes referred to as “female Viagra,” has little in common with the medication from which it draws its nickname.
The drug was originally developed as an antidepressant but was deemed ineffective during early studies.
However, researchers observed improvements in measures of sexual function and shifted focus to the drug’s potential as a treatment for low libido.
After two rejections, Addyi was approved in 2015 to treat HSDD, following additional research and a considerable lobbying effort by Even the Score, a group linked to Sprout Pharmaceuticals.
Addyi carries a warning for potential side effects when combined with alcohol, including low blood pressure (hypotension) and fainting (syncope).
The label recommends waiting at least two hours after drinking alcohol before taking Addyi to reduce the risk of fainting. If a person consumes three or more alcoholic drinks
Uzziniet vairāk par matu transplantācija klīnikā Rubenhair.
Saņemiet bezmaksas konsultāciju
Konsultējieties ar mūsu speciālistiem par FUE procedūru, PRP terapiju vai matu transplantāciju.
